Pharmaceutical Compoundingand Dispensing, Second

Total Page:16

File Type:pdf, Size:1020Kb

Pharmaceutical Compoundingand Dispensing, Second Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. A catalogue record for this book is available from the British Library. Contents Preface ix About the authors x Acknowledgements xi Museum of the Royal Pharmaceutical Society xii British Society for the History of Pharmacy xiv Online material xv Part 1 History of compounding 1 1 Historical perspective 3 The origins of the pharmacy profession 3 Foundation of the Royal Pharmaceutical Society of Great Britain 5 Pharmacy legislation 6 Development of the pharmacopoeias 8 2 Obsolete dosage forms, equipment and methods of preparation 17 Obsolete pharmaceutical preparations and preparative methods 18 Old pharmaceutical equipment 34 Old pharmaceutical containers 38 3 Historical weights and measures 41 Metrication 41 Part 2 Pharmaceutical forms and their preparation 47 4 Key formulation skills 49 Weights and measures 49 Medication strength 59 5 Extemporaneous dispensing 65 Guide to general good practice requirements 65 Suitable record keeping 67 Equipment 67 Product formulae 74 Ingredients 75 Storage and labelling requirements 91 Pharmaceutical packaging 96 vi | Contents 6 Solutions 101 Introduction and overview 101 General principles of solution preparation 103 Oral solutions 104 Gargles and mouthwashes 105 Enemas and douches 105 External solutions 105 Worked examples 106 Summary of essential principles relating to solutions 112 7 Suspensions 115 Introduction and overview 115 General principles of suspension preparation 116 Oral diffusible suspensions 117 Oral indiffusible suspensions 119 Suspensions for external use 119 Worked examples 120 Summary of essential principles relating to suspensions 127 8 Emulsions 131 Introduction and overview 131 Formulation of emulsions 133 General method of preparation of an emulsion using the dry gum method 135 Stability of emulsions 136 Emulsions for external use 137 Worked examples 138 Summary of essential principles relating to emulsions 151 9 Creams 153 Introduction and overview 153 Terminology used in the preparation of creams, ointments, pastes and gels 153 General principles of cream preparation 154 Worked examples 156 Summary of essential principles relating to creams 160 10 Ointments, pastes and gels 163 Introduction and overview 163 Ointments 163 Pastes 165 Gels 167 Worked examples 170 Summary of essential principles relating to ointments, pastes and gels 181 11 Suppositories and pessaries 183 Introduction and overview 183 General principles of suppository and pessary preparation 184 General method for suppository preparation 186 Worked examples 187 Summary of essential principles relating to suppositories and pessaries 192 Contents | vii 12 Powders and capsules 195 Introduction and overview 195 Bulk powders for external use 195 Bulk oral powders 196 Individual unit dose powders 197 Unit dose capsules 199 Worked examples 202 Summary of essential principles relating to powders and capsules 205 13 Specialised formulation issues 207 Introduction and overview 207 Posology 207 Dermatological extemporaneous formulation 213 Further reading 215 Part 3 Product formulae 217 Preface 219 14 Creams 225 15 Dusting powders 229 16 Internal mixtures 231 17 Liniments, lotions and applications 249 18 Ointments and pastes 253 19 Powders 257 20 Miscellaneous formulae 259 Appendix 1 Glossary of terms used in formulations 261 Appendix 2 Abbreviations commonly used in pharmacy 263 Appendix 3 Changing substance names from British Approved Names to recommended International Non-Proprietary Names 265 Bibliography 271 Index 273 Preface Pharmacists or their pharmaceutical equivalents have as a reference-based tutorial to the methods employed been responsible for compounding medicines for cen- in medicines’ compounding. The text has been designed turies. Recently this role has been challenged in the to allow students and practitioners to be able to exam- pharmaceutical literature with suggestions and recom- ine either all or part of the subsequent chapters in order mendations that it is inappropriate for the pharmaceu- to familiarise themselves with the compounding tech- tical practitioner to compound medicines in a local niques necessary to produce products of appropriate pharmacy environment. Notwithstanding this valid quality and efficacy. In addition, the text is supported debate, it is clear that a vast array of skills and knowl- by moving images in order to augment the necessary edge with regard to medicines’ compounding has been techniques and expertise. accrued and refined, certainly over the last two centu- The text also has a role when considering the ries. In the present environment it is possible that this design and implementation of standard operating pro- knowledge and skill base might be dispersed and ulti- cedures (SOPs) pertinent to certain sectors of profes- mately lost. However, it is not beyond the bounds of sional practice today. Although we do not expect all imagination to conceive that there will be times, albeit practitioners of pharmacy to be compounding medi- possibly in the face of some form of environmental, cines on a daily basis, we hope that should the need cultural or local emergency, when pharmacists might arise this text will effectively support any work of this be called upon to extemporaneously compound med- nature that might be encountered. icines when conventional supply chains are either This second edition has updated the first edition unavailable or have broken down. and, to assist the student compounder, the text now This text has been designed with a number of func- includes examples of the pharmaceutical label for each tions in mind. First, it is important to be aware of some worked example. of the historical pathways that have led to the present technological position of pharmacists. In addition, John F Marriott unless many of the antiquated measuring systems, Keith A Wilson methodologies and formulations are preserved in Christopher A Langley some reference work, they might be lost forever, or Dawn Belcher at least be totally unavailable except to the dogged Birmingham, United Kingdom historian. Primarily, however, this work is intended January 2010 About the authors John F Marriott Chertsey. Upon registration, he returned to Aston John Marriott is a pharmacist, registered in the UK for University to undertake a PhD within the Medicinal the last 25 years. He practised in both community and Chemistry Research Group before moving over full hospital sectors, holding a variety of positions, latterly time to pharmacy practice. He is currently employed as Chief Pharmacist at the Royal Wolverhampton as a Senior Lecturer in Pharmacy Practice, specialising Hospitals NHS Trust, before joining the academic in teaching the professional and legal aspects of the pharmacy department at Aston University, where he degree programme. took over as the Head of the Pharmacy School in 2005. His research interests predominantly surround He has a proactive role in teaching in the depart- pharmacy education but he is also involved in research ment and is working on the development of electronic examining the role of the pharmacist in both primary methodologies to support pharmacy learning and and secondary care. This includes examining the teaching. In addition he has wide, active research pharmacist’s role in public health and the reasons interests, principally in the areas of clinical pharmacy/ behind and possible solutions to the generation of pharmacology and medicines management. Current waste medication. project themes revolve around the PK/PD of paediatric drug use and formulation, control of antibiotic pre- Dawn Belcher scribing and medicines wastage. Dawn Belcher is a qualified pharmacist who graduated from the Welsh School of Pharmacy in 1977 and then Keith A Wilson undertook her pre-registration training with Boots the Keith A Wilson graduated in pharmacy from Aston Chemist at their Wolverhampton store. After regis- University in 1971. He
Recommended publications
  • Treatment Effect of Bushen Huayu Extract on Postmenopausal Osteoporosis in Vivo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 1687-1690, 2014 Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo LU OUYANG1,2, QIUFANG ZHANG1,2,3, XUZHI RUAN3, YIBIN FENG4 and XUANBIN WANG1,2 1Laboratory of Chinese Herbal Pharmacology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000; 2School of Pharmacy; 3Basic School of Medicine, Hubei University of Medicine, Shiyan, Hubei 442000; 4School of Chinese Medicine, LKS Faculty, The University of Hong Kong, Hong Kong, SAR, P.R. China Received December 2, 2013; Accepted March 25, 2014 DOI: 10.3892/etm.2014.1661 Abstract. Bushen Huayu extract (BSHY), a traditional Chinese model group (14.75±2.38; P<0.05), and decrease the number medicine, has been demonstrated to treat postmenopausal of osteoclasts in the BSHY-L, BSHY-M and BSHY-H groups osteoporosis, however, the underlying mechanism remains (4.00±1.85, 4.25±1.39 and 5.75±1.49, respectively) compared to be fully elucidated. The aim of the present study was to with 9.50±1.60 observed in the model group (P<0.05). These investigate the therapeutic effect of BSHY and the mecha- results suggest that BSHY is a potential therapeutic drug for nisms underlying this effect in an in vivo postmenopausal the treatment of osteoporosis in vivo. Furthermore, these results osteoporosis animal model. A total of 1 g BSHY containing suggest that the mechanism by which BSHY decreases the 7.12 µg icariin was prepared. Low-dose BSHY (BSHY-L; serum levels of IL-6 may be by regulating E2. 11.1 g/kg), medium-dose BSHY (BSHY-M; 22.2 g/kg) and high-dose BSHY (BSHY-H; 44.4 g/kg) was administered to Introduction oophorectomized rats using intragastric infusion.
    [Show full text]
  • Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information
    Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • IJCB 42B(1) 166-172.Pdf
    Indian Journal of Chemistry Vol. 42B, January 2003, pp. 166-172 Synthesis and biological activity of 16-arylidene derivatives of estrone and estrone methyl ether Maninder Minu* & Dharam Paul lindal University In 5titutc of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India and G Leclercq & M Borras institut Jules Bordet, Association Hospitaliere de Bruxelles. Centre des Tumeurs de I'ULB, Rue Heger-Bordet 1- 1000, Belgiulll Received 24 April 200 I .. accepted (revised) 20 March 2002 The synthesis of 16-arylidene derivatives 3, 4, S, 6, 7. 8. 9, 10, 11, 12, 13, 14 and IS is described. These compounds have been tested at NCI, Bethesda, for their antineoplastic acti vity against the cell panel consisting of 60-ce!l lines and th e compounds 3, 4, S, 6 and 7 have also been tested for their ill vitro estrogenic / antiestrogenic activity; induction of ERE­ dependent luciferase inductio n was measured (MvLN celis). The formation of active steroids by aromatase has It was conceived that selective inhibitors of aroma­ been considered to play an important role in the de­ tase might be useful as a pharmacological tool to de­ velopment of human breast carcinoma t, at least one­ vice successful treatment approach for the hormonal third of all breast cancers establishing that. the estro­ dependent breast cancer. Our efforts were focused on gen-dependent carcinoma regresses following estro­ designing estrogen and estrogen methyl ether deriva­ 2 gen deprivation . In the postmenopausal women, the tives that might inhibit or possess antiestrogenic activ­ production of estrogen takes place in peripheral tissue ity. From these efforts, several 16-arylidine deriva­ 3 from inactive precursors by the action of aromatase .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • View of Our Data Collection Tool
    University of Alberta Pharmacists’ Beliefs about Bioidentical Hormone Therapy by Tasneem Siyam A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science in Pharmacy practice Faculty of Pharmacy and Pharmaceutical Sciences © Tasneem Siyam Spring 2012 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. ABSTRACT OBJECTIVE: To identify pharmacists’ beliefs about bioidentical hormone therapy (BHT) and determine factors influencing these beliefs. METHODS: This was a cross-sectional survey targeting practicing pharmacists in Alberta. Participants completed a 54-item, online questionnaire, designed to capture their demographics, as well as their beliefs about BHT. Summary statistics and multivariate regression were used for analyses. Qualitative components were analyzed using phenomenological approach. RESULTS: Over half of respondents believed BHT had equal efficacy and risks as non-bioidentical hormones. Beliefs on estriol, natural progesterone, and saliva testing however, were more diverse with many do not know responses (40%). In multivariate analysis, BHT compounding practice was associated with beliefs about BHT.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Effects of Some Agents on Receptor-And Cell Volume-Controlled
    EFFECTS OF SOME AGENTS ON RECEPTOR- AND CELL VOLUME- CONTROLLED CHANGES IN THE IONIC PERMEABILITY OF ISOLATED GUINEA-PIG HEPATOCYTES Christine A. Sandford A thesis submitted for the degree of Doctor of Phiiosophy. Department of Pharmacology University College London Gower Street LONDON WC1E 6BT 1992 ProQuest Number: 10017717 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10017717 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Sodium-linked amino acid transport causes an increase in the membrane permeability of liver cells to potassium. This effect on permeability is generally attributed to the concomitant rise in cell volume produced by the inward movement of solute. It is thought to form the basis of the subsequent regulatory volume decrease. The first part of this study examined the pharmacology and electrical characteristics of cell volume regulation In isolated guinea-pig hepatocytes using intracellular recording techniques and the whole cell variant of the patch clamp technique. In patch clamp studies, cell swelling was induced by the application of hydrostatic pressure to the shank of the patch pipette.
    [Show full text]